Program
ubrogepant
Also written as “Ubrogepant”, “MK-1602” and “Ubrogepant 100 mg”.
Its studies are mostly in Migraine Disorders, led by AbbVie.
Furthest: phase 4, since Feb 22, 202213 company-led studies, 3 open or runningNext primary completion: May 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 133 open or running | phase 4since Feb 22, 2022 | May 16, 2012 | May 2027phase 3 · NCT05125302 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 16, 2012First study: phase 2 study in Migraine DisordersFirst studyNCT01613248 · 834 enrolled
- Aug 2, 2012Phase 2 study in Migraine DisordersNCT01657370 · 195 enrolled
- Jul 7, 2016Phase 3 study in Migraine DisordersNCT02828020 · 1,672 enrolled · United States
- Aug 12, 20162 phase 3 studies in Migraine DisordersNCT02867709, NCT02873221
- Sep 26, 2019Phase 1 study in Migraine DisordersNCT04179474 · 40 enrolled · United States
- Jul 27, 2020Phase 3 study in Migraine DisordersNCT04492020 · 518 enrolled · United States
- Mar 24, 2021Phase 1 study in Migraine DisordersNCT04818515 · 26 enrolled · United States
- Nov 8, 20212 phase 3 studies in Migraine DisordersNCT05125302, NCT05127954
- Feb 22, 2022Phase 4 study in Episodic MigraineNCT05264129 · 263 enrolled · United States
- May 13, 2024Phase 3 study in Migraine DisordersNCT06417775 · 496 enrolled · United States, Puerto Rico
- Jun 26, 2026Phase 1 study in Healthy VolunteerNCT07680686 · 52 enrolled · United States
Ahead
- May 2027Primary completion: phase 3 study in Migraine DisordersNCT05125302
- Nov 2027Primary completion: phase 3 study in Migraine DisordersNCT06417775
- Jan 2028Primary completion: phase 3 study in Migraine DisordersNCT05127954
TargetBeta
“An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the acute treatment of migraines”NCIt, by rule
“Calcitonin gene-related peptide type 1 receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| atogepantrule | AbbVie | phase 4 | 19 |
| zavegepantrule | Pfizer | phase 3 | 13 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07680686Healthy Volunteer · United States | 1 | Completed | Oct 16, 2026 | 52 |
| NCT06417775Migraine Disorders · United States, Puerto Rico | 3 | Active, not recruiting | Nov 2027 | 496 |
| NCT05264129Episodic Migraine · United States | 4 | Completed | Apr 4, 2023 | 263 |
| NCT05127954Migraine Disorders · United States, Puerto Rico | 3 | By invitation | Jan 2028 | 1,200 |
| NCT05125302Migraine Disorders · United States, Puerto Rico | 3 | Recruiting | May 2027 | 1,059 |
| NCT04818515Migraine Disorders · United States | 1 | Completed | Jun 18, 2021 | 26 |
| NCT04492020Migraine Disorders · United States | 3 | Completed | Apr 19, 2022 | 518 |
| NCT04179474Migraine Disorders · United States | 1 | Completed | Dec 23, 2019 | 40 |
| NCT02873221Migraine Disorders · United States | 3 | Completed | Aug 2, 2018 | 1,254 |
| NCT02867709Migraine Disorders · United States | 3 | Completed | Jan 25, 2018 | 1,686 |
| NCT02828020Migraine Disorders · United States | 3 | Completed | Dec 13, 2017 | 1,672 |
| NCT01657370Migraine Disorders | 2 | Completed | Nov 2012 | 195 |
| NCT01613248Migraine Disorders | 2 | Completed | Dec 1, 2012 | 834 |
How it is read
Names in the registry
- “Ubrogepant”, 11 entries
- “MK-1602”, 2 entries
- “Ubrogepant 100 mg”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 12 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.